Piper Jaffray Companies cut shares of Novan (NASDAQ:NOVN) from an overweight rating to a neutral rating in a research report sent to investors on Sunday, The Fly reports. They currently have $0.50 price target on the stock.
Several other research analysts have also recently issued reports on NOVN. ValuEngine cut Novan from a sell rating to a strong sell rating in a research report on Friday, January 3rd. Zacks Investment Research cut Novan from a hold rating to a sell rating in a research report on Saturday, November 16th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $1.75.
Shares of NASDAQ:NOVN opened at $0.76 on Friday. The stock has a market cap of $21.91 million, a price-to-earnings ratio of -0.67 and a beta of 2.06. Novan has a 12-month low of $0.65 and a 12-month high of $3.72. The business’s 50 day moving average is $2.25 and its 200 day moving average is $2.46.
Several large investors have recently made changes to their positions in NOVN. Vanguard Group Inc. boosted its position in Novan by 38.8% in the second quarter. Vanguard Group Inc. now owns 456,346 shares of the company’s stock worth $1,232,000 after purchasing an additional 127,534 shares during the last quarter. Renaissance Technologies LLC boosted its position in Novan by 49.3% in the second quarter. Renaissance Technologies LLC now owns 201,949 shares of the company’s stock worth $545,000 after purchasing an additional 66,658 shares during the last quarter. BlackRock Inc. boosted its position in Novan by 105.6% in the second quarter. BlackRock Inc. now owns 95,990 shares of the company’s stock worth $260,000 after purchasing an additional 49,305 shares during the last quarter. Prospera Financial Services Inc boosted its position in Novan by 11.8% in the third quarter. Prospera Financial Services Inc now owns 95,435 shares of the company’s stock worth $246,000 after purchasing an additional 10,083 shares during the last quarter. Finally, RMB Capital Management LLC boosted its position in Novan by 21.3% in the second quarter. RMB Capital Management LLC now owns 57,000 shares of the company’s stock worth $154,000 after purchasing an additional 10,000 shares during the last quarter. 5.56% of the stock is currently owned by institutional investors.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Recommended Story: Price-Sales Ratio
Receive News & Ratings for Novan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan and related companies with MarketBeat.com's FREE daily email newsletter.